DYAI: Dyadic International Inc Company Value to Net Income

Dyadic - graphic logo of issuer DYAI

The market trend visualized in monetary format on the GURU.Markets platform serves as an indicator for Dyadic International (DYAI), where the current figure is -1.80. Business growth is based on the implementation of the C1 system for budget protein synthesis and the receipt of partner payments, which facilitates expansion into the agrochemical and medical sectors. Dyadic International (DYAI) acts as a technological ally to global laboratories, scaling vaccine production.

DYAI - Dyadic International, Inc. P/E Multiple over the range 07/04/2022 - 11/10/2026

Analytical breakdowns for Dyadic International Inc (DYAI)

- price and consensus price forecast:
Stock Price Dyadic|DYAI - Consensus Target
- market capitalization information:
Market Value Dyadic International, Inc.|DYAI - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Dyadic International|DYAI - Book Capitalization|Market Capitalization to Book Value dyadic.com|DYAI - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Dyadic International|DYAI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Dyadic|DYAI - Company Debts|Debts to Net Assets Dyadic International, Inc.|DYAI - Company Long-Term Debts|Company Short-Term Indebtedness Dyadic International|Immediate Liquidity dyadic.com
- earnings and market ratios statistics:
DYAI - Net Profit|Projected Future Earnings Dyadic International|DYAI - P/E Multiple|Price to Future Earnings Ratio Dyadic|DYAI - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Dyadic International, Inc.|DYAI - Operating profit EBITDA|Net earnings per share for the last 12 months Dyadic International|DYAI - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months dyadic.com|DYAI - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Dyadic International
Comprehensive company analysis:Dyadic International
Flagship merchandise of Dyadic International Inc

Investors are valuing Dyadic International (DYAI) through the ratio of the current market share price to earnings per share, which determines the capital payback period. By analyzing the company's P/E ratio, market expectations can be compared with the value of the C1 patent platform, which ensures low vaccine production costs and creates a long-term foundation for the asset's fundamental undervaluation.

Key competitors

P/E Multiple gilead.com|Price to Earnings Ratio CDTX (Cidara Corp)|NVAX (Novavax Inc) - Company Value to Net Income|CureVac Corp - Price to Earnings Ratio|Valneva Vaccines - Price to Earnings Ratio|Vir Biotechnology, Inc. - P/E Multiple|Business Payback Period siga.com SIGA|Emergent BioSolutions Inc. (EBS) - Price to Earnings Ratio|Atea Pharma - Company Value to Net Income|Price to Earnings Ratio IVVD|P/E Multiple Enanta Pharmaceuticals, Inc|Price to Earnings Ratio Inovio Pharmaceuticals (INO)|Business Payback Period hillevax.com|P/E Multiple KLRS (Kalaris Therapeutics)|NNVC: Price to Earnings Multiple|TLPH: Price to Earnings Ratio|Market Cap to Earnings Cocrystal Pharma Corp|TRAW: P/E Multiple|Dogwood Therapeutics (DWTX) - P/E Multiple|QLGN (Qualigen Therapeutics, Inc.) - P/E Multiple|Price to Earnings Multiple ALVR (AlloVir Bio)|P/E Multiple VBIV|Business Payback Period virios.com|P/E Multiple VXRT (Vaxart)